Zobrazeno 1 - 10
of 121
pro vyhledávání: '"William S. Fletcher"'
Autor:
Su Ellen Toth-Fejel, Rodney F. Pommier, William S. Fletcher, Joshua Schmidt, Katherine T. Morris
Publikováno v:
Surgery. 130:947-953
Stage IV hormone-sensitive breast cancer is often treated with aromatase inhibitors (anastrozole, letrozole, exemestane), which block the conversion of dehydroepiandrosterone (DHEA) to estrone and estradiol. This is intended to obviate the need for s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dc7e9edc7c785aeb5ae2a97aec0047e
https://doi.org/10.1067/msy.2001.118378
https://doi.org/10.1067/msy.2001.118378
Autor:
Cynthia Gail Leichman, James H. Doroshow, Joth R. Jacobson, John S. Macdonald, Mark M. Zalupski, William S. Fletcher, Manuel Modiano, John R. Daniels
Publikováno v:
Cancer. 86:775-781
BACKGROUND Rates of response to systemic chemotherapy among patients with advanced colorectal carcinoma rarely exceed 25– 30%, and complete responses are rare. The liver is the most common site of metastasis; however, regional therapies have not im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0284b3a806bf66ac8e67472baf27a0b
https://doi.org/10.1002/(sici)1097-0142(19990901)86:5<775::aid-cncr12>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19990901)86:5<775::aid-cncr12>3.0.co
Autor:
William S. Fletcher, Michael Walker, Joseph M. Unger, Lawrence E. Flaherty, Kim Margolin, Vernon K. Sondak, Jeffrey A. Sosman, John W. Smith, Geoffrey R. Weiss, P. Y. Liu
Publikováno v:
Journal of Clinical Oncology. 16:664-669
PURPOSE The combination of carmustine (BCNU), dacarbazine (DTIC), cisplatin (DDP), and tamoxifen (Tam) has been reported in small series to provide a response rate of 50%, but with significant myelosuppression and risk of thromboembolic complications
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf7950654478af22d9fab3650a1d2f90
https://doi.org/10.1200/jco.1998.16.2.664
https://doi.org/10.1200/jco.1998.16.2.664
Autor:
Eugene A. Woltering, Karen A. Small, Leslie Rand-Luby, William S. Fletcher, Shauna T. Williams, Rodney F. Pommier
Publikováno v:
Annals of Surgery. 224:583-590
OBJECTIVE: The objective of this study was to analyze the effect of dimethylsulfoxide (DMSO) on skin flap viability. BACKGROUND: Dimethylsulfoxide has been shown to decrease necrosis of random skin flaps in the rat model, but no human studies have be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62ca998da10e1b5494dc727b6153a084
https://doi.org/10.1097/00000658-199610000-00016
https://doi.org/10.1097/00000658-199610000-00016
Autor:
William S. Fletcher, Ronald L. Stephens, Lawrence E. Flaherty, P. Y. Liu, Michael Walker, Malcolm S. Mitchell, Vernon K. Sondak, John Wendall Goodwin
Publikováno v:
American Journal of Clinical Oncology. 19:108-113
Based on the reports of substantial improvement in the response rate w ith the addition of tamoxifen to a multiagent chemotherapy regimen for metastatic melanoma, Southwest Oncology Group (SWOG)-8921 was initiated. A prior regimen (SWOG-8804) of daca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2352367002988ab072671b9e010f9f78
https://doi.org/10.1097/00000421-199604000-00004
https://doi.org/10.1097/00000421-199604000-00004
Autor:
William S. Fletcher, P. Y. Liu, John A. Thompson, Jeffrey A. Sosman, Vernon K. Sondak, Lawrence E. Flaherty, Alexander Hantel
Publikováno v:
Investigational New Drugs. 13:83-87
Piroxantrone is one of the anthrapyrazoles developed in an effort to combine the broad antitumor activity of the anthracyclines with decreased myocardial toxicity. It has shown activity in metastatic melanoma during phase I trials. The Southwest Onco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ab8493a97042a20e31cef6420c8ce46
https://doi.org/10.1007/bf02614226
https://doi.org/10.1007/bf02614226
Autor:
William S. Fletcher, Leslie Rogers Laufman, Vernon K. Sondak, Kenneth J Kopecky, P. Y. Liu, Walter H Harvey
Publikováno v:
Anti-Cancer Drugs. 5:147-150
Didemnin B is a cyclic peptide isolated from the marine tunicate Trididemnin cyanophorum. It is a known potent inhibitor of RNA, DNA and protein synthesis, with activity against the murine B16 melanoma. Fourteen patients with disseminated malignant m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21e436986f12b2998ec0a62bb3596cc1
https://doi.org/10.1097/00001813-199404000-00004
https://doi.org/10.1097/00001813-199404000-00004
Autor:
M Boileau, Brent A. Blumenstein, William S. Fletcher, Antoinette J. Wozniak, E D Crawford, Saul E. Rivkin
Publikováno v:
Cancer. 71:3975-3978
Background. Hormone-refractory metastatic prostate cancer remains a therapeutic challenge. Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), a drug combination that is active in solid tumors, was evaluated using specific response criteria. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c96459a8429810781a6acc9e0129a60a
https://doi.org/10.1002/1097-0142(19930615)71:12<3975::aid-cncr2820711229>3.0.co
https://doi.org/10.1002/1097-0142(19930615)71:12<3975::aid-cncr2820711229>3.0.co
Autor:
Michael K. Samson, Kenneth J. Kopecky, D. D. Von Hoff, Raymond A. Kempf, Franco M. Muggia, William S. Fletcher, Julie A. Kish
Publikováno v:
Investigational New Drugs. 9:105-108
Twenty-seven evaluable patients with advanced malignant melanoma received fludarabine phosphate in a daily x 5 injection. Initial dosing was based on the presence of previous radiation therapy. There was no response seen in these patients despite app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b57e12fcfdbdb7610c9d031b9fccaad
https://doi.org/10.1007/bf00194559
https://doi.org/10.1007/bf00194559
Autor:
William S. Fletcher, Shauna T. Williams, Louis Lebrado, Eugene A. Woltering, Thomas M. O'Dorisio
Publikováno v:
Metabolism. 39:176-179
Somatostatin and its longer-acting analog, octreotide acetate, can be used effectively for the treatment of nonendocrine gastrointestinal disorders. Octreotide has been shown to decrease pancreatic fistula output by suppressing exocrine pancreatic fu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9ec501b631f212d213da2b76b0b83aa
https://doi.org/10.1016/0026-0495(90)90240-d
https://doi.org/10.1016/0026-0495(90)90240-d